Postmenopausal Vaginal Atrophy Global Clinical Trials Review, H2, 2017
Overview
Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence.
Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2627295-vaginal-atrophy-atrophic-vaginitis-pipeline-review-h2-2017
Top Companies mentioned
Allergan Plc
Medinova AG
Mithra Pharmaceuticals SA
Sermonix Pharmaceuticals LLC
TherapeuticsMD Inc
Vaginal Atrophy Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Vaginal Atrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vaginal Atrophy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 2, 1, 1 and 1 respectively.
Vaginal Atrophy pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Vaginal Atrophy - Competitive Analysis
Key players are making innovative developments in Vaginal Atrophy industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy.
The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Vaginal Atrophy therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Vaginal Atrophy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy.
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2627295-vaginal-atrophy-atrophic-vaginitis-pipeline-review-h2-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by
Vivian Dsena
on Tuesday February 27 2018, 6:46 AM EST.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
